ストックスクリーナーアプリを入手
2.77
25.91%
0.57
前日終値:
$2.20
開ける：
$2.21
24時間の取引高:
22.61M
Relative Volume:
21.71
時価総額：
$91.94M
収益：
-
当期純損益:
$-98.79M
株価収益率:
-0.8471
EPS:
-3.27
ネットキャッシュフロー:
$-51.66M
1週間 パフォーマンス:
+13.06%
1か月 パフォーマンス:
+19.40%
6か月 パフォーマンス:
+658.70%
1年 パフォーマンス:
-19.01%
1日の値動き範囲:
$2.19
$2.81
1週間の範囲:
$2.15
$2.81
52週間の値動き範囲:
$0.2404
$3.50
Relmada Therapeutics Inc Stock (RLMD) Company Profile
名前
Relmada Therapeutics Inc
セクター
電話
646 876 3459
住所
2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY
RLMD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| 3.03 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
2.50 | 4.21B | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
19.99 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
4.825 | 217.47M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.2288 | 502.27M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
DAVEW
Dave Inc
|
1.3695 | 0 | 0 | 0 | 0 | 0.00 |
Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-05 | ダウングレード | Mizuho | Outperform → Neutral |
| 2024-09-17 | アップグレード | Jefferies | Hold → Buy |
| 2024-06-05 | ダウングレード | Goldman | Neutral → Sell |
| 2022-10-14 | ダウングレード | Goldman | Buy → Neutral |
| 2022-10-14 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-10-14 | ダウングレード | Truist | Buy → Hold |
| 2022-10-13 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2021-11-18 | 開始されました | Mizuho | Buy |
| 2021-05-20 | 再開されました | Goldman | Buy |
| 2020-10-28 | ダウングレード | Goldman | Buy → Neutral |
| 2020-07-14 | 開始されました | Oppenheimer | Outperform |
| 2020-05-04 | 開始されました | SunTrust | Buy |
| 2020-04-21 | 開始されました | Goldman | Buy |
| 2020-01-27 | 開始されました | Jefferies | Buy |
| 2020-01-10 | 開始されました | SVB Leerink | Outperform |
| 2019-12-16 | 開始されました | Guggenheim | Buy |
すべてを表示
Relmada Therapeutics Inc (RLMD) 最新ニュース
Relmada Therapeutics Moves: Max Kates Joins Advisory Board - StocksToTrade
Relmada Therapeutics (RLMD) Advances Phase 3 Plans for Bladder C - GuruFocus
Relmada Therapeutics prices $100M securities offering - MSN
Relmada Therapeutics (RLMD) Launches $100 Million Stock and Warr - GuruFocus
Relmada Therapeutics stock falls after $100 million share offering By Investing.com - Investing.com UK
Relmada Therapeutics stock falls after $100 million share offering - Investing.com
Relmada Therapeutics prices $100 million stock offering at $2.20 per share - Investing.com
Relmada Therapeutics Receives FDA Feedback on NDV-01 Trials - TipRanks
Relmada’s NDV-01 shows 92% response rate in bladder cancer - Investing.com
Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - The Manila Times
Relmada Therapeutics Announces 9-Month Follow-Up Safety and Efficacy Data for NDV-01 in Non-Muscle Invasive Bladder Cancer, with FDA Support for Future Registrational Trials - Quiver Quantitative
Relmada Therapeutics (NASDAQ: RLMD) prices 40,142,000-share offering for $100M - Stock Titan
Relmada (NASDAQ: RLMD) posts 92% ORR in NMIBC as FDA supports two Phase 3 paths - Stock Titan
Why Relmada Therapeutics Inc. stock remains a top recommendationJuly 2025 Chart Watch & Precise Entry and Exit Recommendations - newser.com
What institutional flow reveals about Relmada Therapeutics Inc.Long Setup & Weekly Watchlist of Top Performers - newser.com
Will Relmada Therapeutics Inc. stock recover faster than marketMarket Volume Summary & Low Risk Entry Point Guides - newser.com
Smart tools for monitoring Relmada Therapeutics Inc.’s price actionJuly 2025 Weekly Recap & Fast Exit and Entry Strategy Plans - newser.com
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Short Interest Update - MarketBeat
What to expect from Relmada Therapeutics Inc. in the next 30 days - newser.com
Is Relmada Therapeutics Inc. building a consolidation baseJuly 2025 Trends & Low Risk Profit Maximizing Plans - newser.com
Is Relmada Therapeutics Inc. stock ready for a breakoutEarnings Growth Summary & Fast Gain Stock Trading Tips - newser.com
Why Relmada Therapeutics Inc. stock is a value investor pickJuly 2025 EndofMonth & Fast Momentum Entry Tips - newser.com
Will breakout in Relmada Therapeutics Inc. lead to full recoveryNew Guidance & Community Trade Idea Sharing - newser.com
Is Relmada Therapeutics Inc. showing signs of accumulation2025 Technical Patterns & Fast Entry High Yield Tips - newser.com
Will Relmada Therapeutics Inc. (4E2) stock beat revenue estimatesWall Street Watch & Stock Portfolio Risk Control - newser.com
Why Relmada Therapeutics Inc. stock attracts global investors2025 Growth vs Value & Daily Momentum Trading Reports - newser.com
Will Relmada Therapeutics Inc. stock gain from lower inflationIndex Update & Low Risk High Reward Ideas - newser.com
Relmada Therapeutics (NASDAQ:RLMD) Given Sell (E+) Rating at Weiss Ratings - MarketBeat
AdvisorShares Investments LLC Raises Stock Holdings in Relmada Therapeutics, Inc. $RLMD - MarketBeat
Relmada Therapeutics (RLMD) to Release Earnings on Thursday - MarketBeat
Relmada Therapeutics Inc (RLMD) 財務データ
収益
当期純利益
現金流量
EPS
Relmada Therapeutics Inc (RLMD) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| TRAVERSA SERGIO | Chief Executive Officer |
Aug 26 '25 |
Buy |
0.62 |
80,545 |
49,938 |
814,569 |
| TRAVERSA SERGIO | Chief Executive Officer |
Aug 28 '25 |
Buy |
0.74 |
55,976 |
41,422 |
1,000,000 |
| Kelly Paul Edward | Chief Operating Officer |
May 16 '25 |
Buy |
0.43 |
200,000 |
86,060 |
412,295 |
| Shenouda Maged | Chief Financial Officer |
May 19 '25 |
Buy |
0.49 |
90,000 |
43,686 |
228,335 |
| Shenouda Maged | Chief Financial Officer |
May 20 '25 |
Buy |
0.52 |
60,000 |
31,422 |
288,335 |
| Shenouda Maged | Chief Financial Officer |
May 16 '25 |
Buy |
0.44 |
50,000 |
22,100 |
138,335 |
| Ence Chuck | CA and CO |
May 16 '25 |
Buy |
0.45 |
228,961 |
103,330 |
267,931 |
| TRAVERSA SERGIO | Chief Executive Officer |
May 20 '25 |
Buy |
0.56 |
147,686 |
82,246 |
734,024 |
| TRAVERSA SERGIO | Chief Executive Officer |
May 16 '25 |
Buy |
0.45 |
172,314 |
77,472 |
556,338 |
| TRAVERSA SERGIO | Chief Executive Officer |
May 19 '25 |
Buy |
0.50 |
30,000 |
14,994 |
586,338 |
1.45%
0.86%
大文字化:
|
ボリューム (24 時間):